Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UK's Ofcom requires tech firms to create crisis response plans
- Micron to deliver 'another strong quarter', Goldman says
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Supermicro plans $7 billion financing to fund AI server orders
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
August 14, 2025 7:00 AM EDTInitial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025
Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label study
FDA recommended that the safety database include at least 30... More
